Vanda Pharmaceuticals (NASDAQ:VNDA) Director Charles Cliff Duncan Buys 3,447 Shares of Stock

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Charles Duncan acquired 3,447 shares of the company’s stock in a transaction on Wednesday, November 4th. The shares were bought at an average cost of $3.82 per share, with a total value of $13,167.54. Following the acquisition, the director directly owned 102,898 shares in the company, valued at approximately $393,070.36. The trade was a 3.47% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Charles Cliff Duncan also recently made the following trade(s):

• On Thursday, November 5th, Charles Duncan bought 5,803 shares of Vanda Pharmaceuticals stock. The stock was purchased at an average cost of $3.80 per share, for a total transaction of $22,051.40.
• On Tuesday, November 3rd, Charles Duncan bought 750 shares of Vanda Pharmaceuticals stock. The stock was purchased at an average cost of $3.80 per share, for a total transaction of $2,850.00.

Vanda Pharmaceuticals Price Performance

Shares of Vanda Pharmaceuticals stock opened at $3.59 on Friday. The stock has a 50 day moving average of $4.66 and a 200 day moving average of $6.14. Vanda Pharmaceuticals Inc. has a 12 month low of $3.57 and a 12 month high of $9.94. The firm has a market cap of $217.09 million, a PE ratio of -0.78 and a beta of 0.74. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.31. Vanda Pharmaceuticals had a negative return on equity of 62.70% and a negative net margin of 119.87%. The business had revenue of $69.81 million for the quarter, compared to the consensus estimate of $69.20 million. On average, research analysts expect that Vanda Pharmaceuticals Inc. will post -2.53 EPS for the current fiscal year.

Key Vanda Pharmaceuticals News

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Director Charles Cliff Duncan bought a combined 10,000 shares from November 3–5 for approximately $38,069, increasing his ownership. SEC ownership filing
• Neutral Sentiment: HC Wainwright maintained its Buy rating and raised its 2026 EPS estimate to a loss of $2.45 from a loss of $3.03, including a narrower projected Q4 loss.
• Negative Sentiment: HC Wainwright lowered estimates for Q2–Q4 2027 and cut its full-year 2027 EPS forecast to a loss of $1.02 from a loss of $0.94, signaling a less favorable outlook for those periods.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC raised its position in Vanda Pharmaceuticals by 8.8% during the first quarter. Hsbc Holdings PLC now owns 38,855 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 3,144 shares during the period. Quantbot Technologies LP bought a new stake in shares of Vanda Pharmaceuticals in the 2nd quarter valued at approximately $29,000. Legal & General Group Plc purchased a new position in Vanda Pharmaceuticals during the second quarter worth $34,000. Allworth Financial LP purchased a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth about $43,000. Finally, SG Americas Securities LLC raised its position in Vanda Pharmaceuticals by 94.7% in the 1st quarter. SG Americas Securities LLC now owns 21,042 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 10,235 shares during the period. 88.14% of the stock is owned by institutional investors.

Analyst Ratings Changes

VNDA has been the subject of a number of recent research reports. Zacks Research lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 6th. B. Riley Financial reaffirmed a “buy” rating and set a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research note on Monday, August 10th. Wall Street Zen upgraded shares of Vanda Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 31st. Oppenheimer began coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Thursday, October 15th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Vanda Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $13.50.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.